Close Menu

NEW YORK – Angiocare will distribute Spartan Bioscience's test for CYP2C19 mutations, the firms announced on Thursday.

The deal covers the Netherlands, where Angiocare is based, although it may eventually cover other geographies, a spokesperson for Spartan Bio said. She declined to disclose further details.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.